experimental group:apatinib mesylate

4 trials

Sponsors

People's Hospital of Inner Mongolia Autonomous Region, He'nan Cancer Hospital, The Second Affiliated Hospital of Nanchang University, Xiangya Hospital of Central South University, Hunan Cancer Hospital, The First Affiliated Hospital of Zhengzhou University

Conditions

Hepatocellular carcinomaOral CancerThyroid cancerUnresectable hilar cholangiocarcinoma

Phase 4

Preliminary efficacy of apatinib mesylate tablets in the treatment of unresectable hilar cholangiocarcinoma

RecruitingChiCTR1900022746

People's Hospital of Inner Mongolia Autonomous RegionUnresectable hilar cholangiocarcinoma

Start: 2019-05-01Updated: 2019-04-30

Clinical study of apatinib mesylate in patients with refractory thyroid cancer

Active, not recruitingChiCTR2000033531

He'nan Cancer HospitalThyroid cancer

Start: 2020-06-15Updated: 2020-06-08

A prospective, multi-center clinical study of apatinib mesylate in the treatment of advanced hepatocellular carcinoma

Active, not recruitingChiCTR2100044142

The Second Affiliated Hospital of Nanchang University, Xiangya Hospital of Central South University, Hunan Cancer HospitalHepatocellular carcinoma

Start: 2021-03-01Updated: 2021-08-30

A single-arm, single-center, exploratory study of Apatinib combined with Nedaplatin and Tiggio postoperative adjuvant treatment of oral cancer

Active, not recruitingChiCTR2100048559

The First Affiliated Hospital of Zhengzhou UniversityOral Cancer

Start: 2021-07-15Updated: 2022-03-21